Interferons and interferon inducers in cancer treatment.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000906:Antibodies / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D007369:Interferon Inducers / Q000627:therapeutic use*; D007372:Interferons / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D009369:Neoplasms / Q000628:therapy*; D011070:Poly I-C / Q000627:therapeutic use; D011107:Polylysine / Q000627:therapeutic use / Q000031:analogs & derivatives; D011994:Recombinant Proteins / Q000627:therapeutic use; D009626:Terminology as Topic
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000970:Antineoplastic Agents; D007369:Interferon Inducers; D011994:Recombinant Proteins; D011107:Polylysine; C019531:poly ICLC; D007372:Interferons; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C